| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 22 | 2025 | 250 | 5.270 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2025 | 815 | 3.130 |
Why?
|
| Leukemia, Myeloid, Acute | 14 | 2024 | 570 | 2.530 |
Why?
|
| Neoplasms, Second Primary | 6 | 2025 | 149 | 2.400 |
Why?
|
| Neoplasms | 19 | 2025 | 2961 | 2.170 |
Why?
|
| Thyroid Neoplasms | 4 | 2021 | 251 | 1.920 |
Why?
|
| Telomere | 4 | 2016 | 222 | 1.410 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 294 | 1.200 |
Why?
|
| Hodgkin Disease | 4 | 2024 | 304 | 1.160 |
Why?
|
| Child | 56 | 2025 | 25783 | 1.130 |
Why?
|
| Telomere Shortening | 2 | 2021 | 34 | 1.110 |
Why?
|
| Telomerase | 3 | 2020 | 168 | 1.080 |
Why?
|
| Survivorship | 3 | 2024 | 44 | 1.050 |
Why?
|
| Mycoses | 2 | 2021 | 117 | 0.970 |
Why?
|
| Health Equity | 2 | 2024 | 75 | 0.920 |
Why?
|
| Neutropenia | 5 | 2023 | 205 | 0.900 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2025 | 123 | 0.900 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1348 | 0.880 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 1192 | 0.850 |
Why?
|
| Telomere-Binding Proteins | 3 | 2020 | 45 | 0.840 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2025 | 64 | 0.810 |
Why?
|
| Adolescent | 37 | 2025 | 20557 | 0.810 |
Why?
|
| Dyskeratosis Congenita | 2 | 2013 | 19 | 0.800 |
Why?
|
| Telomere Homeostasis | 2 | 2020 | 45 | 0.740 |
Why?
|
| Patient Preference | 1 | 2023 | 141 | 0.730 |
Why?
|
| Radiotherapy | 3 | 2021 | 145 | 0.720 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 102 | 0.720 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3358 | 0.720 |
Why?
|
| Frailty | 2 | 2021 | 136 | 0.700 |
Why?
|
| Health Status Disparities | 1 | 2024 | 252 | 0.680 |
Why?
|
| Hyperbilirubinemia | 2 | 2022 | 42 | 0.680 |
Why?
|
| Humans | 72 | 2025 | 132247 | 0.660 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 1829 | 0.660 |
Why?
|
| Methotrexate | 5 | 2025 | 351 | 0.650 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 202 | 0.640 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2025 | 194 | 0.640 |
Why?
|
| Antifungal Agents | 3 | 2024 | 314 | 0.620 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 277 | 0.610 |
Why?
|
| Internet | 2 | 2022 | 406 | 0.610 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 108 | 0.600 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 128 | 0.600 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.590 |
Why?
|
| Young Adult | 19 | 2025 | 9966 | 0.570 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 74 | 0.560 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 127 | 0.560 |
Why?
|
| Caregivers | 1 | 2023 | 596 | 0.560 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 13 | 0.550 |
Why?
|
| Down Syndrome | 1 | 2020 | 232 | 0.540 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 165 | 0.540 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 2851 | 0.540 |
Why?
|
| Siblings | 3 | 2019 | 202 | 0.530 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 58 | 0.530 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 328 | 0.510 |
Why?
|
| Infertility | 1 | 2017 | 81 | 0.510 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 81 | 0.500 |
Why?
|
| Genetic Variation | 2 | 2020 | 1580 | 0.500 |
Why?
|
| Cognition Disorders | 1 | 2020 | 571 | 0.490 |
Why?
|
| Female | 40 | 2025 | 70787 | 0.480 |
Why?
|
| Child, Preschool | 20 | 2025 | 14736 | 0.470 |
Why?
|
| Survivors | 5 | 2024 | 358 | 0.470 |
Why?
|
| Prognosis | 9 | 2024 | 5016 | 0.470 |
Why?
|
| Male | 36 | 2025 | 65014 | 0.450 |
Why?
|
| Risk Factors | 16 | 2025 | 10945 | 0.440 |
Why?
|
| Neutrophils | 1 | 2016 | 360 | 0.440 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1683 | 0.410 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 45 | 0.400 |
Why?
|
| Anemia, Aplastic | 1 | 2013 | 60 | 0.390 |
Why?
|
| Proportional Hazards Models | 5 | 2023 | 1461 | 0.380 |
Why?
|
| Papillomavirus Vaccines | 2 | 2025 | 106 | 0.380 |
Why?
|
| Steroids | 1 | 2013 | 174 | 0.380 |
Why?
|
| Induction Chemotherapy | 2 | 2025 | 56 | 0.370 |
Why?
|
| Obesity | 3 | 2018 | 2398 | 0.350 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 34 | 0.340 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 254 | 0.340 |
Why?
|
| Hematology | 1 | 2011 | 41 | 0.330 |
Why?
|
| Incidence | 5 | 2024 | 3376 | 0.330 |
Why?
|
| Cardiomyopathies | 2 | 2025 | 509 | 0.330 |
Why?
|
| Adult | 18 | 2025 | 31614 | 0.330 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 902 | 0.330 |
Why?
|
| Microcephaly | 1 | 2013 | 354 | 0.320 |
Why?
|
| Thrombocytopenia, Neonatal Alloimmune | 1 | 2009 | 2 | 0.310 |
Why?
|
| Isoantibodies | 1 | 2009 | 58 | 0.310 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 385 | 0.310 |
Why?
|
| Wolman Disease | 1 | 2009 | 7 | 0.310 |
Why?
|
| Sterol Esterase | 1 | 2009 | 21 | 0.300 |
Why?
|
| Case-Control Studies | 4 | 2021 | 3414 | 0.300 |
Why?
|
| Cellular Senescence | 1 | 2010 | 201 | 0.300 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2009 | 84 | 0.300 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 5410 | 0.300 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2087 | 0.290 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17395 | 0.290 |
Why?
|
| HLA Antigens | 1 | 2009 | 219 | 0.280 |
Why?
|
| Anthracyclines | 3 | 2025 | 44 | 0.280 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 663 | 0.260 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1500 | 0.250 |
Why?
|
| Societies, Medical | 1 | 2011 | 778 | 0.250 |
Why?
|
| Infant | 12 | 2025 | 13049 | 0.250 |
Why?
|
| Texas | 4 | 2023 | 3632 | 0.250 |
Why?
|
| Electronics | 2 | 2023 | 45 | 0.240 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 120 | 0.240 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1094 | 0.240 |
Why?
|
| Connectin | 1 | 2025 | 29 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1307 | 0.230 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 39 | 0.220 |
Why?
|
| Candida tropicalis | 1 | 2024 | 17 | 0.220 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 23 | 0.220 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2025 | 170 | 0.220 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3995 | 0.220 |
Why?
|
| Medical Oncology | 1 | 2025 | 244 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2025 | 5176 | 0.200 |
Why?
|
| Body Fluids | 1 | 2023 | 47 | 0.200 |
Why?
|
| Metabolome | 1 | 2025 | 324 | 0.200 |
Why?
|
| Dyslipidemias | 1 | 2025 | 241 | 0.190 |
Why?
|
| Genome-Wide Association Study | 3 | 2025 | 1831 | 0.190 |
Why?
|
| Asparaginase | 1 | 2022 | 49 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 56 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 48 | 0.180 |
Why?
|
| Metabolomics | 1 | 2025 | 479 | 0.180 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 48 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 623 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 140 | 0.170 |
Why?
|
| Aftercare | 2 | 2022 | 155 | 0.170 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 140 | 0.170 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 29 | 0.170 |
Why?
|
| Middle Aged | 6 | 2023 | 29021 | 0.170 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 31 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 137 | 0.160 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 956 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 196 | 0.160 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 172 | 0.160 |
Why?
|
| Poverty | 1 | 2023 | 450 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 128 | 0.160 |
Why?
|
| Parents | 2 | 2023 | 1080 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 215 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 185 | 0.150 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8548 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2022 | 323 | 0.150 |
Why?
|
| Fatal Outcome | 2 | 2011 | 376 | 0.150 |
Why?
|
| Introns | 1 | 2020 | 305 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2020 | 158 | 0.150 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 409 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2025 | 801 | 0.150 |
Why?
|
| Aging, Premature | 1 | 2018 | 28 | 0.140 |
Why?
|
| Remission Induction | 2 | 2016 | 306 | 0.140 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1757 | 0.140 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 10 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2020 | 750 | 0.140 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 461 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 197 | 0.140 |
Why?
|
| Heart Atria | 1 | 2020 | 337 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 256 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 302 | 0.140 |
Why?
|
| Stroke Volume | 1 | 2020 | 536 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 608 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 516 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 209 | 0.130 |
Why?
|
| Medulloblastoma | 1 | 2022 | 571 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 2681 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 375 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2018 | 327 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2018 | 130 | 0.130 |
Why?
|
| Longevity | 1 | 2018 | 159 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2020 | 408 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 548 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1444 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 857 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 670 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2020 | 1233 | 0.120 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 253 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 590 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 511 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2025 | 3736 | 0.120 |
Why?
|
| Alleles | 1 | 2020 | 1685 | 0.120 |
Why?
|
| Quality of Life | 2 | 2024 | 2161 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2018 | 396 | 0.110 |
Why?
|
| Biopsy | 1 | 2018 | 1288 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 846 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 43 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 43 | 0.110 |
Why?
|
| Echocardiography | 1 | 2020 | 1126 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 926 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 56 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1725 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1128 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1418 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 1163 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 553 | 0.100 |
Why?
|
| Mutation | 2 | 2020 | 6250 | 0.100 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 146 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 327 | 0.100 |
Why?
|
| Pedigree | 2 | 2014 | 1724 | 0.100 |
Why?
|
| Epilepsy | 1 | 2020 | 891 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 143 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 358 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 368 | 0.090 |
Why?
|
| Age Distribution | 1 | 2013 | 437 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 697 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2018 | 1122 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 1001 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 548 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1444 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 535 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1574 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2009 | 30 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 2314 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1161 | 0.070 |
Why?
|
| Liver Failure | 1 | 2009 | 91 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2010 | 454 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2025 | 6568 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 502 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 302 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 1254 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 2010 | 550 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1410 | 0.060 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 30 | 0.060 |
Why?
|
| Selection Bias | 1 | 2024 | 19 | 0.050 |
Why?
|
| Pediatrics | 2 | 2025 | 1210 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 200 | 0.050 |
Why?
|
| Apoptosis | 1 | 2010 | 1901 | 0.050 |
Why?
|
| Risk | 2 | 2018 | 761 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 1453 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 105 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 42 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 242 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 827 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 348 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 183 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2022 | 240 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2021 | 87 | 0.040 |
Why?
|
| Creatinine | 1 | 2023 | 413 | 0.040 |
Why?
|
| Biomarkers | 1 | 2010 | 3404 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 2923 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 251 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2022 | 303 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4540 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 990 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 802 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 40 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 205 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 425 | 0.040 |
Why?
|
| Vaccination | 1 | 2025 | 1018 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 306 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 383 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 780 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 486 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1081 | 0.040 |
Why?
|
| Family | 1 | 2021 | 595 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 220 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 456 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2020 | 13027 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 662 | 0.030 |
Why?
|
| Bleomycin | 1 | 2018 | 113 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 167 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1249 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 237 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 755 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 186 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1338 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7557 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 1591 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 576 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 899 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 804 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 24 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 1902 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 702 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3018 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 2664 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 1700 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 881 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3761 | 0.020 |
Why?
|
| Aged | 2 | 2023 | 21482 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6451 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 1556 | 0.020 |
Why?
|
| Gangliosides | 1 | 2010 | 73 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1087 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 248 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2166 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 294 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3093 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 1045 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 234 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1080 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 686 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 473 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1285 | 0.020 |
Why?
|
| United States | 1 | 2020 | 11669 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2680 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2511 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 4720 | 0.010 |
Why?
|